Small Molecules

04 Apr 2007 Repros┬┤ Proellex Shows Statistically Significant Improvement in Primary Endpoint in Phase 2 Trial in the Treatment of Uterine Fibroids
04 Apr 2007 FDA Grants Fast Track Designation to Alzheimer┬┤s Disease Drug Candidate AZD-103/ELND005
04 Apr 2007 Icagen Terminates Phase III ASSERT Study
04 Apr 2007 Trexima(TM) (Sumatriptan/Naproxen Sodium) Superior Efficacy Data Published in JAMA
03 Apr 2007 Senetek PLC Grants Paid Up License to Valeant Pharmaceuticals
03 Apr 2007 Alkermes Submits Marketing Authorization Application for VIVITROL(R) in the United Kingdom and Germany
03 Apr 2007 Theravance Announces Positive Results of Clinical Program in Beyond Advair Collaboration
03 Apr 2007 FDA Approves JANUMET(TM) for Type 2 Diabetes, Offering Powerful Glucose Control of a DPP-4 Inhibitor and Metformin in a Single Tablet
03 Apr 2007 Genelabs Technologies Receives Agreement from FDA on Special Protocol Assessment for Phase III Trial of Prestara in Lupus
31 Mar 2007 Xeloda Approved in Europe for the Treatment of Advanced Stomach Cancer
31 Mar 2007 Novartis suspends US marketing and sales of Zelnorm(R) in response to request from FDA
31 Mar 2007 Safety Analyses of Clinical Data for Bifeprunox in Patients with Schizophrenia Showed a Favorable Weight and Lipid Profile, Similar to Placebo
31 Mar 2007 Progenics and Wyeth Announce Submission of New Drug Application for the Subcutaneous Formulation of Methylnaltrexone for the Treatment of Opioid-Induced Constipation in Patients Receiving Palliative Care
31 Mar 2007 Takeda to Obtain Development and Commercial Rights
31 Mar 2007 CanBas and Takeda to Sign the Collaboration Agreement
31 Mar 2007 NEOPHARM Provides Update on LE-SN38 Program
31 Mar 2007 Cephalon Provides Update Related to NUVIGIL(TM) New Drug Application
30 Mar 2007 EPIX Pharmaceuticals Initiates Phase 2b Clinical Trial of PRX-00023 in Patients with Major Depressive Disorder
30 Mar 2007 NicOx Announces that Pfizer has Disclosed Further Details of Glaucoma Trial for PF-03187207
30 Mar 2007 Emisphere Technologies, Inc. Reports Clinical Data on Oral Delivery of GLP-1 and PYY
30 Mar 2007 Arpida announces promising results of "first-in-man" studies with AR-709
30 Mar 2007 Enzon Enrolls First Patient in Phase 1 Study of Its HIF-1 Alpha Antagonist
30 Mar 2007 Hollis-Eden Pharmaceuticals Announces Filing of IND for Phase I Clinical Trial with Next-Generation Drug Candidate HE3286 in Metabolic Disorders
29 Mar 2007 Anesiva Commences Phase 3 Clinical Study of Zingo(TM) to Treat Pain Associated With Venous Access Procedures in Adults
29 Mar 2007 Clinical Development Initiated on Lead Compound in NicOx Glaucoma Collaboration with Pfizer

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2018 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up